Overview Dividends

(GPCR) Structure Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US86366E1064

GSBR-1290, ACCG-2671, ANPA-0073, LTSE-2578, GIPR Program

EPS (Earnings per Share)

EPS Growth (3y CAGR): 27.92%
EPS Trend (3y Corr): -6.6%

Last SUE: -0.17σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): 0.00%
Revenue Trend (3y Corr): 9.0%

Last SUE: 0.00σ
Qual. Beats: 0

Risk via 10d forecast
Volatility	89.6%
Value at Risk 5%th	118%
Relative Tail Risk	-19.85%

Reward TTM
Sharpe Ratio	0.37
Alpha	-2.88

Character TTM
Hurst Exponent	0.419
Beta	0.845
Beta Downside	1.177

Drawdowns 3y
Max DD	80.96%
Mean DD	43.31%
Median DD	47.56%

Description: GPCR Structure Therapeutics November 15, 2025

Structure Therapeutics Inc. (NASDAQ: GPCR) is a clinical-stage biotech that focuses on orally administered small-molecule agonists for chronic metabolic disorders, primarily obesity and related weight-management indications. Its lead asset, GSBR-1290, is a biased GLP-1 receptor agonist currently enrolled in two Phase 2 trials targeting obesity and overweight patients in the United States.

The pipeline also includes preclinical ACCG-2671 (another oral obesity candidate), a Phase 2-ready apelin-receptor agonist ANPA-0073 aimed at selective or muscle-sparing weight loss, and LTSE-2578, an LPA1 antagonist being evaluated for idiopathic pulmonary fibrosis. In addition, Structure is advancing a suite of GIPR and GCGR small-molecule programs that could yield dual-agonist or antagonist profiles for obesity and metabolic disease.

Key sector metrics that shape Structure’s upside: the global GLP-1 market is projected to exceed $30 billion by 2028, and oral GLP-1 agents are expected to capture a premium share due to improved patient adherence. As of the latest 10-Q, GPCR reported $78 million in cash and equivalents, giving it roughly 18 months of runway at its current burn rate of $4-5 million per month. The company’s market capitalization hovers around $150 million, implying a price-to-cash ratio of ~2×, which is modest relative to peers with comparable pre-revenue pipelines.

For a deeper quantitative assessment, you may find the ValueRay platform’s model on GPCR useful.

GPCR Stock Overview

Market Cap in USD	2,124m
Sub-Industry	Biotechnology
IPO / Inception	2023-02-03
Return 12m vs S&P 500	-6.14%
Analyst Rating	4.57 of 5

GPCR Dividends

Currently no dividends paid

GPCR Growth Ratios

Metric	Value
CAGR 3y	34.57%
CAGR/Max DD Calmar Ratio	0.43
CAGR/Mean DD Pain Ratio	0.80
Current Volume	1408.2k
Average Volume	937.8k

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-210.7m TTM) > 0 and > 6% of Revenue (6% = 106.9k TTM)

FCFTA -0.24 (>2.0%) and ΔFCFTA -12.41pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 42.5k% (prev 66.9k%; Δ -24.5kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.23 (>3.0%) and CFO -194.2m > Net Income -210.7m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 14.15 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (58.5m) change vs 12m ago 2.24% (target <= -2.0% for YES)

Gross Margin 13.49% (prev -8.18%; Δ 21.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 0.20% (prev 0.14%; Δ 0.06pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -8.19 (EBITDA TTM -238.3m / Interest Expense TTM -29.2m) >= 6 (WARN >= 3)

Altman Z'' -6.32

(A) 0.91 = (Total Current Assets 814.0m - Total Current Liabilities 57.5m) / Total Assets 832.2m

(B) -0.60 = Retained Earnings (Balance) -503.3m / Total Assets 832.2m

(D) -8.09 = Book Value of Equity -502.5m / Total Liabilities 62.1m

Total Rating: -6.32 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 30.22

1. Piotroski 0.0pt

2. FCF Yield -14.75%

3. FCF Margin data missing

4. Debt/Equity 0.01

5. Debt/Ebitda 0.40

6. ROIC - WACC (= -38.78)%

7. RoE -26.08%

8. Rev. Trend 9.02%

9. EPS Trend -6.62%

What is the price of GPCR shares?

As of November 21, 2025, the stock is trading at USD 34.34 with a total of 1,408,247 shares traded.
Over the past week, the price has changed by -1.89%, over one month by +23.21%, over three months by +84.97% and over the past year by +4.98%.

Is GPCR a buy, sell or hold?

Structure Therapeutics has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy GPCR.

Strong Buy: 8
Buy: 6
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the GPCR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	73.6	114.4%
Analysts Target Price	73.6	114.4%
ValueRay Target Price	36.9	7.5%

GPCR Fundamental Data Overview November 15, 2025

Market Cap USD = 2.12b (2.12b USD * 1.0 USD.USD)
P/B = 2.758
Beta = -1.742
Revenue TTM = 1.78m USD
EBIT TTM = -239.4m USD
EBITDA TTM = -238.3m USD
Long Term Debt = 7.09m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.80m USD (from shortTermDebt, last quarter)
Debt = 7.09m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -95.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.33b USD (2.12b + Debt 7.09m - CCE 799.0m)
Interest Coverage Ratio = -8.19 (Ebit TTM -239.4m / Interest Expense TTM -29.2m)
FCF Yield = -14.75% (FCF TTM -196.4m / Enterprise Value 1.33b)
FCF Margin = -11.0k% (FCF TTM -196.4m / Revenue TTM 1.78m)
Net Margin = -11.8k% (Net Income TTM -210.7m / Revenue TTM 1.78m)
Gross Margin = 13.49% ((Revenue TTM 1.78m - Cost of Revenue TTM 1.54m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.60 (Enterprise Value 1.33b / Total Assets 832.2m)
Interest Expense / Debt = 84.74% (Interest Expense 6.01m / Debt 7.09m)
Taxrate = -0.16% (negative due to tax credits) (108.0k / -65.6m)
NOPAT = -239.8m (EBIT -239.4m * (1 - -0.16%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 14.15 (Total Current Assets 814.0m / Total Current Liabilities 57.5m)
Debt / Equity = 0.01 (Debt 7.09m / totalStockholderEquity, last quarter 770.0m)
Debt / EBITDA = 0.40 (negative EBITDA) (Net Debt -95.8m / EBITDA -238.3m)
Debt / FCF = 0.49 (negative FCF - burning cash) (Net Debt -95.8m / FCF TTM -196.4m)
Total Stockholder Equity = 807.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.32% (Net Income -210.7m / Total Assets 832.2m)
RoE = -26.08% (Net Income TTM -210.7m / Total Stockholder Equity 807.9m)
RoCE = -29.38% (EBIT -239.4m / Capital Employed (Equity 807.9m + L.T.Debt 7.09m))
RoIC = -29.68% (negative operating profit) (NOPAT -239.8m / Invested Capital 807.9m)
WACC = 9.10% (E(2.12b)/V(2.13b) * Re(9.13%) + (debt cost/tax rate unavailable))
Discount Rate = 9.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.27%
Fair Price DCF = unknown (Cash Flow -196.4m)
EPS Correlation: -6.62 | EPS CAGR: 27.92% | SUE: -0.17 | # QB: 0
Revenue Correlation: 9.02 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for GPCR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle